Johnson & Johnson Booster Showed Efficacy in South Africa During Omicron Prevalence
December 30 2021 - 06:13AM
Dow Jones News
By Matt Grossman
Johnson & Johnson's booster vaccine for Covid-19 was 85%
effective against hospitalization in a study conducted in South
Africa after the Omicron variant became dominant, the company said
Thursday.
The study was conducted among healthcare workers in South Africa
who had received a single shot of the Johnson & Johnson vaccine
as their primary vaccination. Vaccine efficacy against
hospitalization increased to 85% after a booster shot, even after
Omicron became the most widespread strain in the region, New
Brunswick, N.J.-based Johnson & Johnson said.
A separate study of vaccine regimens found that the company's
booster vaccine increased the immune response when administered to
patients who had received a different primary vaccine, Johnson
& Johnson said. The Johnson & Johnson booster generated a
41-fold increase in neutralizing antibody responses and a 5-fold
increase in CD8+ T-cells to Omicron by four weeks following the
boost, the company said.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
December 30, 2021 06:58 ET (11:58 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024